Results 201 to 210 of about 58,715 (292)

Systemic Drivers and Molecular Mechanisms of Sarcopenia in Aetiology‐Specific End‐Stage Liver Disease

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Patients with end‐stage liver disease (ESLD) often present with sarcopenia, defined as loss of skeletal muscle mass and quality, which is associated with reduced quality of life and increased mortality. However, the molecular mechanisms driving sarcopenia in ESLD are not fully understood and there are currently no therapeutic ...
Thomas Nicholson, Sophie L. Allen, Jonathan I. Quinlan, Amritpal Dhaliwal, Michael Macleod, Joshua Price, Jon Hazeldine, Michael S. Sagmeister, Caitlin Ditchfield, Kirsty C. McGee, Felicity R. Williams, Ahmed M. Elsharkawy, Matthew J. Armstrong, Carolyn A. Greig, Janet M. Lord, Leigh Breen, Simon W. Jones   +16 more
wiley   +1 more source

The role of systemic inflammation in hepatic encephalopathy: advances in inflammatory mechanisms, prevention and treatment research. [PDF]

Ann Med
Wang W, Wen Y.
europepmc   +1 more source

Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Background Cachexia and sarcopenia are prevalent, inflammation‐linked syndromes in chronic liver disease that worsen outcomes. To our knowledge, their coexistence in a single chronic liver disease cohort has not been systematically examined.
Takatsugu Tanaka, Goki Suda, Masatsugu Ohara, Daisuke Yokoyama, Shoichi Kitano, Osamu Maehara, Tomoka Yoda, Qingjie Fu, Zijian Yang, Naohiro Yasuura, Akimitsu Meno, Takashi Sasaki, Risako Kohya, Takashi Kitagataya, Naoki Kawagishi, Masato Nakai, Takuya Sho, Shunsuke Ohnishi, Naoya Sakamoto   +18 more
wiley   +1 more source

Clinical Challenges in the Management of Hepatic Encephalopathy in Older Patients with Cirrhosis: A Nationwide Italian Physician-Reported Survey. [PDF]

Medicina (Kaunas)
Lapenna L, Di Cola S, Nardelli S, Merli M.   +3 more
europepmc   +1 more source

Development of a Clinical Severity Score for Indian Sickle Cell Anaemia Patients

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Sickle cell anaemia (SCA) is a monogenic disorder but shows variable disease severity. We evaluated the utility of paediatric severity scores (PSS) in Indian patients and developed two modified scores: Indian Severity Score 1 (ISS1) by adding four clinical parameters to PSS, and ISS2 by excluding four biochemical measures from ISS1.
Suraj S. Nongmaithem, Amitabh Biswas, Swaroop Iyer, Jandhayala Vyshnavi, Archana Wath, Giriraj R. Chandak, Dipty Jain   +6 more
wiley   +1 more source

Case Report: A case of hepatic encephalopathy secondary to a spontaneous splenorenal shunt. [PDF]

Front Surg
An Y, Deng C, Wen C, Liu J, Zhu Y, Chen K, Luo H.   +6 more
europepmc   +1 more source

European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B‐Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community‐Based Centers and for Outpatient Step‐Up Dosing

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Safe outpatient delivery of B‐cell maturation antigen–targeting bispecific antibodies (BCMA‐BsAbs) in multiple myeloma (MM) is challenging, particularly during step‐up dosing (SUD). Standardized guidance for European community practice is limited.
María‐Victoria Mateos, Elena Zamagni, Massimo Gentile, Rachel Hall, Florence Lachenal, Mónica López Riñon, Rakesh Popat, Christof Scheid, Thomas Wolff, Isabel Perez‐Cruz, Mohamad Mohty   +10 more
wiley   +1 more source

Prospective evaluation of speech as a digital biomarker for covert hepatic encephalopathy. [PDF]

NPJ Digit Med
Gazda J, García-Pagán JC, Drazilova S, Drotar P, Hires M, Gazda M, Janicko M, Baiges A, Jarcuska P.   +8 more
europepmc   +1 more source

Biological Drivers of IMiD‐Induced Peripheral Neuropathy in Multiple Myeloma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, making treatment‐related side effects increasingly important.
Sina A. Beer, Richard Houlston, Martin F. Kaiser   +2 more
wiley   +1 more source

Serum metabolomics identifies GPC depletion in hepatic encephalopathy and its therapeutic potential for cognitive impairment. [PDF]

Front Pharmacol
Chen H, Xing X, Ding X, Xiang G, Li J, Yang Y, Liu Q, Xu K, Lei Q, Li P.   +9 more
europepmc   +1 more source